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transposons and g-retroviruses have been efficiently used as insertional mutagens in different tissues to identify molecular culprits of cancer. however, these systems are characterized by recurring integrations that accumulate in tumor cells and that hamper the identification of early cancer-driving events among bystander and progression-related events. We developed an insertional mutagenesis platform based on lentiviral vectors (lVVs) by which we could efficiently induce hepatocellular carcinoma (hcc) in three different mouse models. By virtue of the lVV's replication-deficient nature and broad genomewide integration pattern, lVV-based insertional mutagenesis allowed identification of four previously unknown liver cancer-associated genes from a limited number of integrations. We validated the oncogenic potential of all the identified genes in vivo, with different levels of penetrance. the newly identified genes are likely to play a role in human cancer because they are upregulated, amplified and/or deleted in human hccs and can predict clinical outcomes of patients.
The approaches most frequently used to discover genes that are altered in cancer are high-throughput 'omics' technologies. However, because bystander lesions are also frequent, the causeeffect relationships of cancer-associated alterations, especially in late-stage tumors, are not always obvious 1 . Insertional mutagenesis approaches use oncoretroviruses or transposons to trigger cancer in mice by widespread integration into the cellular genome and activation of oncogenes near the integration site. Mapping the genomic integration sites in tumors allows the identification of genomic regions that are recurrently hit in independent tumors (defined as common insertion sites (CISs)), which host genes likely to be involved in cancer development 2 .
We have shown that human immunodeficiency virus (HIV)derived LVVs with long terminal repeats (LTRs) containing strong enhancer-promoter sequences are prone to induce insertional mutagenesis 3 . Here we show that these tools can be applied for cancer gene discovery in the mouse. Because LVVs are able to efficiently transduce quiescent cells and a variety of tissues and organs in vivo [4] [5] [6] [7] [8] [9] [10] [11] , including liver 12 , here we developed an LVV specifically tailored to induce HCC in mice (LV.ET.LTR) by activating and tagging cancer genes in hepatocytes. We used LV.ET.LTR to screen for liver cancer genes in three mouse models. First, we screened in Cdkn2 −/− Ifnar1 −/− mice, whose genotype combines the high sensitivity to genotoxic mutations conferred by the Cdkn2a deficiency 13 with the high permissiveness to hepatocyte gene transfer by LVV conferred by the Ifnar1 deficiency 14 . CDKN2A and its targets-pRB and p53-are frequently inactivated or silenced in human HCCs 15 . Second, as the inflammatory microenvironment plays a fundamental role in the pathogenesis of human HCC 16 , we used a mouse model of liver-specific Pten deficiency (Pten livernull) that recapitulates several aspects of human non-alcoholic steatohepatitis and is characterized by chronic oxidative damage to liver, which, after a long latency period, results in the development of hepatic adenomas and HCCs 17 . PTEN expression is reduced or absent in almost 50% of human HCCs, and it is associated with a poor prognosis 18 . Third, we set up an experimental model of chronic liver injury in wild-type mice by carbon tetrachloride (CCl 4 ) administration, which results in waves of hepatocyte necrosis and regeneration that cause liver damage without progression to cancer. By LVV-based insertional mutagenesis, we induced HCC in these three mouse models and identified four HCC-associated genes that figure prominently in human hepatocarcinogenesis.
results lVV-based insertional mutagenesis
We constructed a transgene-less LVV with highly active hepatospecific enhancer-promoter sequences (enhanced transthyretin, ET 19 ) in the LTR (LV.ET.LTR, Fig. 1a ) to activate genes upon integration in hepatocytes and avoid unwanted effects in nonparenchymal cells. LV.ET.LTR was administered to newborn mice by temporal vein injection, a protocol chosen because substantial levels of hepatocyte transduction can be achieved by a single injection (up to 60% of hepatocytes, Supplementary Fig. 1a ). We tested LV.ET.LTR in three different mouse models of hepatocarcinogenesis: Cdkn2 −/− Ifnar1 −/− mice, Pten liver-null mice and wild-type mice that did or did not receive CCl 4 treatment ( Fig. 1b, Supplementary Fig. 1b-f and Online Methods).
Upon LVV administration, mice of all three models developed HCCs at a frequency significantly higher than that of genotypematched control mice (Fig. 1c-f and Supplementary Fig. 1g-n) . All the HCCs that arose in LVV-treated mice were vector marked ( Supplementary Table 1 ). LVV integrations were retrieved from 30 LVV-induced liver tumors by linear amplification-mediated PCR (LAM-PCR) ( Supplementary Fig. 2a ), resulting in a total of 172 unique integration sites ( Supplementary Table 2a ).
We considered as putative HCC causal genes those recurrently targeted by LVV integrations in independent tumors at a frequency significantly higher than that expected for a random distribution (CISs). On the basis of previous statistical definitions 20, 21 , four CIS genes were identified: Fign (targeted by nine LVV integrations), Braf (four integrations), Sos1 (four integrations) and the Dlk1-Dio3 region (nine integrations) ( Fig. 2a-d and Supplementary Table 2a ). None of the CISs found in tumors was targeted by LVV integrations retrieved from tumor-free livers (n = 162), and no CISs were identified from these control data of insertions ( Supplementary Table 2b ), thus indicating that the CISs identified in HCCs were not determined by an intrinsic genomic integration bias of LVV in hepatocytes.
All the integrations within CISs were in the same transcriptional orientation as the targeted gene. Using reverse-transcriptase PCR (RT-PCR), we detected chimeric LVV-CIS gene-fusion transcripts that contained the LVV sequence from the transcription start site in the 5′ LTR to the major HIV splice donor site fused to the splice acceptor site of an exon of the targeted gene and its remaining coding sequence ( Fig. 2a-d and Supplementary Fig. 2b ). In the case of Braf and Sos1, the products encoded by these fusion transcripts are truncated proteins with increased activity due to the lack of the N-terminal regulatory domains 22,23 ( Fig. 2e and Supplementary Fig. 2c ). LVV-Fign fusion transcripts encode a putative FIGN protein lacking 11 amino acids from the N terminus.
LVV integrations within the Dlk1-Dio3 region generate fusion transcripts with the full-length Rtl1 transcript.
the newly identified cis genes can cause hcc
We tested the oncogenic potential of the newly identified putative cancer genes upon forced expression in mouse hepatocytes in vivo. We generated LVVs with self-inactivating (SIN) LTRs in which the expression of the putative oncogene is regulated by the ET promoter in an internal position and by a 3′ UTR bearing target sequences for microRNA Mir142. These constructs (SIN.ET.LVs) allow high levels of transgene expression restricted to hepatocytes 24 , and the SIN LTR design prevents insertional mutagenesis 3 . Newborn Cdkn2 −/− Ifnar1 −/− (n = 25) or wild-type mice (n = 6) were systemically injected with SIN.ET.LV preparations (2 × 10 7 -4 × 10 8 transducing units (TUs) per mouse; see Online Methods) ( Fig. 2f and Supplementary  Table 3 ). One of five Cdkn2 −/− Ifnar1 −/− mice treated with the vector encoding truncated SOS1 and two of seven Cdkn2 −/− Ifnar1 −/− mice treated with the vector encoding truncated BRAF developed multifocal HCCs. All Cdkn2 −/− Ifnar1 −/− mice (nine out of nine) transduced with the vectors coding for full-length or truncated FIGN developed multiple early-onset HCCs that were lethal by 9 weeks of age. Although unable to induce HCCs in Cdkn2 −/− Ifnar1 −/− mice, Rtl1 overexpression induced HCC in two out of four wild-type mice treated with CCl 4 . The SIN.ET.LVs expressing full-length SOS1 (n = 4 Cdkn2 −/− Ifnar1 −/− mice) or the neutral EGFP-encoding gene (n = 8 Cdkn2 −/− Ifnar1 −/− mice and n = 2 wild-type mice treated with CCl 4 ) did not detectably induce tumors ( Fig. 2g-l, Supplementary Fig. 2d and Supplementary Table 3 ). TFBSs in Synth-E:  C/EBP; DPB; HNF1;  HNF3; HNF4; HNF6 TTR-E TTR-P Figure 1 | Lentiviral vector-mediated induction of HCC. (a) Schematic of LV.ET.LTR vector supplementary note 1). The enhanced transthyretin enhancer-promoter sequence (ET) 19 was cloned in the long terminal repeat (LTR). ET contains a synthetic enhancer (Synth-E) bearing transcription factor binding sites (TFBSs) highly active in hepatocytes (indicated) and the transthyretin enhancer (TTR-E) and transthyretin promoter (TTR-P). SD, splice donor site; SA, splice acceptor site; mPRE, woodchuck posttranscriptional regulatory element, mutated sequence. (b) Experimental outline for LVV-mediated insertional mutagenesis. (c) Liver tumor incidence (%) in different experimental groups (P values by two-tailed Fisher's exact test; *P < 0.05, **P < 0.01). n, number of mice; LVV, LV.ET.LTRtransduced group; UNTR, nontransduced age-matched control groups. Mice were euthanized if sick or at the final time point indicated on the right.
(d-f) Hematoxylin-and eosin-stained sections of livers and HCC masses from the Cdkn2 −/− Ifnar1 −/− mouse model (d), Pten flox/flox AlbCre + mouse model (e) and wild-type mouse model (f; left and center panels, wild type with CCl 4 ; right panel, wild type without CCl 4 ). Left panels show tumorfree liver parenchyma from 30-week (d), 35- week (e) and 1-year-old wild-type mouse treated with CCl 4 (f). Middle and right panels show tumor masses of different grades. Asterisks indicate tumor areas; otherwise, only the tumor tissue is shown. Scale bar, 100 µm. npg the newly identified cancer genes dictate hcc phenotype Integrations targeting Braf, Rtl1 and Fign were found mainly in independent tumors and were significantly associated with grade 3, 2 and 1 HCCs, respectively (Braf P = 0.0026, Rtl1 P < 0.0001 and Fign P = 0.0016, two-tailed Fisher's exact test). HCCs with integrations targeting Sos1 were mainly grade 1. Braf integrations were found only in HCCs from Cdkn2 −/− Ifnar1 −/− mice (P = 0.0004) ( Fig. 3a) . We interrogated by microarray the whole transcriptome of 21 HCCs and 8 nontumoral livers (Gene Expression Omnibus (GEO): GSE31409). CIS genes targeted by integration always showed a significant upregulation as compared to other HCCs or nontumoral livers ( Fig. 3b and Supplementary Fig. 3a,b ). Analyzing the signal intensity of the single probes spanning the mRNAs of the different CIS genes, we verified that vector integrations within Braf, Fign and Sos1 induced the significant overexpression of transcripts containing only exons downstream of the integration ( Fig. 3c ; P values by unpaired t-test).
Through hierarchical unsupervised clustering, we identified four main clusters, each composed of HCCs with the same CIS, such as Rtl1 (cluster of eight HCCs out of eight HCCs harboring integrations targeting Rtl1), Braf (three out of three), Sos1 (two out of three) and Fign (five out of seven) ( Fig. 4a) . By gene set enrichment analysis (GSEA) (Online Methods), we compared the expression profiles of Braf, Fign and Rtl1 HCCs to the profiles of nontumoral tissues and observed the common downregulation of genes involved in hepatic metabolism and the upregulation of genes involved in cancer, cell cycle, growth and proliferation ( Supplementary Fig. 3c and Supplementary Table 4a ,b). We also found relevant differences among the different groups (Fig. 4b,c and Supplementary Fig. 3e-g 
). Fign and Braf
HCCs shared the upregulation of E2f and Yy1 transcriptional targets ( Supplementary  Fig. 3g and Supplementary Table 4a ,b) and the downregulation of oxidative phosphorylation genes ( Supplementary Fig. 3e) . Several oxidative phosphorylation genes and SF1 transcription factor target genes were upregulated in Rtl1 HCCs with respect to other groups and nontumoral liver ( Fig. 4b, Supplementary Fig. 3e and Supplementary Table 4a,b) .
Genes of the WNT signaling pathway were upregulated exclusively in Fign HCCs (Fig. 4c) .
the novel cancer genes are relevant in human hccs
We analyzed a microarray data set (Mount Sinai School of Medicine (MSSM) collection 25 ) constituted by 75 expression profiles from normal and diseased human livers and hepatitis C virus-induced HCCs. We also performed RT-quantitative (q) PCR on HCCs and nontumoral livers from a tissue collection of our institution (Hospital San Raffaele (HSR) collection) ( Fig. 5a-c) . SOS1 was upregulated in 60-70% of all HCCs of both collections, a frequency significantly higher than that observed in nontumoral samples (P < 0.01 and P = 0.02 in the MSSM 25 and HSR collections, respectively; two-tailed Fisher's exact test). In both collections SOS1 was significantly upregulated in HCCs with respect to nontumoral liver (P < 0.001 in MSSM 25 and HSR collections, unpaired t-test) (Fig. 5a ). Furthermore, we found significant SOS1 upregulation by analyzing an independent HCC microarray data set 26 (P < 0.0001, Supplementary Fig. 4a ). FIGN in MSSM HCCs 25 was overexpressed at a frequency significantly higher than that of nontumoral samples (P = 0.008; Fig. 5b ). FIGN is embedded in a chromosomal region that is amplified in human HCCs (Fig. 5d) , and it is also significantly upregulated in human glioblastoma, astrocytoma, oligodendroglioma, melanoma, testicular teratoma and ovarian endometriosis (Supplementary Fig. 4b,c ). In the HSR collection, BRAF expression was significantly higher in HCCs than in nontumoral liver (P < 0.05) ( Fig. 5c) . Moreover, the BRAF locus mapped within a chromosomal region that was amplified in five independent studies on human HCCs (Fig. 5e ). We did not determine the expression level of RTL1 because of the absence of probes in human microarrays and the lack of a RT-qPCR assay that reliably detects T1  T2  T1  T0  T1  T1  T1  T1  T1  T1  T2  T2  T2  T2  T2  T2  T3  T3  T3  T2  T2  N npg the transcript. We found that the chromosomal region containing RTL1 was lost in four independent HCC studies ( Fig. 5f) .
We tested whether the gene expression signatures found in our mouse tumor cohorts by significance analysis of microarray (false discovery rate < 0.01; Online Methods) also had relevance in human hepatocarcinogenesis. GSEA analysis showed that these signatures were significantly enriched in HCCs as compared to healthy tissues or nontumoral diseased tissues in the MSSM collection 25 . The genes downregulated in murine HCCs with Braf or Rtl1 integration were also downregulated in human liver diseases (cirrhosis, dysplasia and HCCs) as compared to normal liver. The genes upregulated in HCCs with Fign integrations were significantly enriched in human disease samples ( Supplementary  Fig. 5a,b) . We then considered the expression levels of the human orthologs of the merged lists of genes from murine CIS-specific gene expression signatures for unsupervised clustering analysis on human liver samples 25 . With unsupervised clustering (Online Methods), the human samples were grouped according to the different phenotypes (normal, cirrhotic, dysplastic or HCC) and the different HCC stages (Supplementary Fig. 5c ).
We investigated the clinical outcomes in a data set of 70 hepatitis B virus-induced HCCs 27 . Patients with HCC with higher expression of SOS1 had a significantly increased overall survival compared to patients with HCC with lower SOS1 levels ( Fig. 5g) . We observed a similar trend in the disease-free survival ( Supplementary Fig. 5d ). Finally, we used the gene expression signature associated with each of the novel cancer genes to classify HCC patients 27 by clustering analysis (Online Methods).
Fign, Rtl1
and Braf signatures identified subgroups of HCC patients characterized by a significantly decreased disease-free survival. These HCC subgroups with poor prognosis displayed aberrant gene expression patterns reminiscent of the gene expression alterations found in the murine HCCs (Fig. 5h,i and Supplementary Fig. 5e-j) .
discussion
We used for the first time, to our knowledge, a replication-defective LVV as an insertional mutagen to induce cancer in mice and to identify molecular culprits of cellular transformation. We efficiently induced HCCs in three different mouse models, generating a collection of 30 HCCs that covered the different grades of the disease (from grade 1 to grade 3) and displayed gene expression signatures reminiscent of those in human HCCs. We identified four CISs (from 172 integrations retrieved from 30 tumors) and observed a strong enrichment for tumors bearing a single CIS integration (83%), when compared to other insertional mutagenesis systems 22, [28] [29] [30] [31] . This high efficiency of CIS retrieval is likely to be the combined result of the nonreplicative nature of LVV, the high efficiency of LVV transduction in hepatocytes and the efficient coverage of genes by integrations.
LVV integrations are produced in a short time window after injection and before the in vivo selection of transformed clones occurs. This results in a lower total number of integrations than γ-retroviruses and transposons produce 22, [28] [29] [30] [31] , which may reduce the incidence of tumor induction and the total yield of identified cancer genes. Although this may represent a limitation of LVVs npg as compared to transposons and γ-retroviruses as insertional mutagens, this characteristic of LVVs may also facilitate the identification of genes that are mutated early in carcinogenesis because it eliminates bystander and progression-related integrations. Identification of early lesions that initiate and drive cellular transformation may be important to unravel pathways essential to the neoplastic phenotype because they may represent early key steps in transformation. Differently from previous studies 22, 28, 30, 31 , three of the cancer genes we identified have not so far been causally implicated in HCC. However, our murine data-driven reanalysis of human HCC data showed that all four of the newly identified genes have clinical relevance in the human disease as well.
Transposable elements are insertional mutagens that, despite overcoming the limited tissue tropism of γ-retroviruses, require the generation of multiple knock-in or transgenic mouse strains. Conversely, LVVs have wide tissue tropism [4] [5] [6] [7] [8] [9] [10] [11] and can be engineered to be oncogenic in different tissues through adaptation of the specificity of the enhancer-promoter sequences, as we have shown in liver and hematopoietic tumors 3 . Therefore, our system complements and extends the insertional mutagenesis screening performed with retroviruses and transposons.
Although they represent a promising insertional mutagenesis tool, LVVs have some potential limitations. First, with LVVs, which are replication deficient, an extensive transduction of the targeted organ is required to obtain significant levels of mutagenesis and eventually cell transformation. Therefore, LVV-mediated insertional mutagenesis may be inefficient in organs that are difficult to access. Second, as with other insertional mutagens, LVVs display a bias for the detection of gainof-function mutations, leading mainly to the identification of oncogenes rather than tumor suppressor genes. Alternative oncogenic LVV designs may be required to overcome these limits. Third, LVVs display integration biases toward expressed genes and gene-dense regions, which could skew the repertoire of identified oncogenes.
We repeatedly found integrations in the four CIS genes in independent tumors. Integrations in specific genes were correlated with a specific genetic background, a specific HCC grade and a specific gene expression signature. Together, these data suggest that the genetic mutation represented by the CIS gene integration is the major determinant of hepatocyte transformation, cancer phenotype and transcriptome alteration.
Although we could qualitatively validate the oncogenic potential of the four cancer genes by in vivo SIN.ET.LV-mediated forced expression in hepatocytes, the incidence of HCC induction was low in some cases. Several variables could explain this low penetrance: (i) some animals may have been transduced at lower levels; (ii) some oncogenes, to induce cell transformation, may require very high levels of expression that are reached in only a minority of hepatocytes in vivo; (iii) conversely, very high SIN.ET.LV-mediated overexpression of constitutively active oncogenes could induce apoptosis and/or counterselection even in Cdkn2a −/− Ifnar1 −/− hepatocytes. Additional studies aimed at quantitatively studying the oncogenic potential of these liver cancer genes are warranted.
The possibility of studying HCC induced by integration in a single CIS allowed us to explore the molecular mechanisms of deregulation of the targeted gene. LVV integrations targeting Braf induced aberrantly spliced mRNAs encoding for a constitutively active protein that was previously reported in insertional mutagenesis studies describing sarcomas in Arf −/− mice 22 and a myeloid tumor in Cdkn2a −/− mice 3 . These data indicate that BRAF activation cooperates with Cdkn2a deficiency to induce cell transformation in different tissues. Furthermore, mutations that constitutively activate BRAF protein were recently found in human HCCs 32 . Finally, the aberrant BRAF form we observed was similar to those found in human thyroid carcinoma, melanoma, and prostate and gastric cancer as a result of translocations or microdeletions 33, 34 .
We showed that ectopic expression of truncated SOS1 protein was able to induce HCCs, whereas the wild-type form was not. SOS1 was overexpressed in human HCCs, and high SOS1 expression correlated with significantly increased overall survival, making SOS1 a candidate prognostic marker for human HCC. Consistent with the human data, murine HCCs induced by LVV-mediated SOS1 truncation were mainly grade 1, less aggressive tumors. Loss-of-function mutations in the RPS6KA3 gene 35 , which encodes an inhibitor of SOS1 signaling 36, 37 , were recently found in human HCCs, further suggesting that activation of the SOS1-BRAF axis has a relevant role in human hepatocarcinogenesis. Moreover, clinical trials have shown that sorafenib, a multikinase inhibitor acting on BRAF, PDGFR and VEGFR, improves the survival of patients with HCC 38 . This may be at least in part mediated by the inhibition of hyperactivated BRAF or SOS1 signaling.
We identified Fign as a target in all mouse models tested, and its overexpression in Cdkn2 −/− Ifnar1 −/− mice triggered rapid HCC onset with 100% penetrance. The oncogenic potential of the truncated FIGN protein was indistinguishable from that of the full-length protein upon LVV-mediated liver gene transfer, suggesting that FIGN overexpression itself has a major impact on oncogenesis. We found that the WNT pathway was deregulated specifically in HCCs induced by integration in Fign. This may shed some light over the putative effectors of this enigmatic gene that we found to be highly relevant in human tumors.
Unlike previous studies that showed deregulation or targeting of maternally expressed genes within the imprinted Dlk1-Dio3 region 39, 40 , we found that LVV integrations targeting the region induced the overexpression of the paternally expressed gene Rtl1 in HCCs. Forced expression of Rtl1 induced HCCs in two out of four wild-type mice treated with CCl 4 , validating the role in hepatocarcinogenesis of this gene, whose pathway and functions are still elusive.
In summary, we developed LVVs carrying highly active enhancer-promoter sequences in the LTRs that are genotoxic in hepatocytes, and we used these tools as insertional mutagens to identify four genes implicated in HCC. The intrinsic versatility, wide tissue tropism and high in vivo transduction efficiency of LVVs will permit effective insertional mutagenesis for the screening of early tumorigenic events in different tissues. Our approach should help identify candidate prognostic markers and therapeutic targets for human HCC and other tumors.
methods
Methods and any associated references are available in the online version of the paper. npg online methods Vector production. We cloned the transfer plasmid for the production of LV.ET.LTR as follows. We eliminated the expression cassette containing hPGK and EGFP from pCCLSIN.cPPT.hPGK. EGFP.wPRE 41 42 , we included by PCR an additional stop codon, and then we cloned the 599-bp product in SalI-EcoRI of pCCLSIN.cPPT.wPRE, thus generating pCCLSIN. cPPT.mwPRE. We blunt-cloned a 31-bp polylinker containing PstI, BamHI, EcoRV, XbaI and NsiI sites at the BbsI site in the −18 SIN LTR. We amplified by PCR a 632-bp fragment containing the ET enhancer-promoter sequence from pCCLsin. cPPT.ET.EGFP.wPRE 24 and carrying NsiI and SpeI at the 5′ and 3′ ends, respectively. Then we cloned it at the PstI and XbaI sites of the previously described polylinker. We then used the resulting plasmid pCCL.ET.LTR.cPPT.mwPRE (see also Supplementary Note 1) for the production of LV.ET.LTR.
For liver gene transfer of putative cancer genes, we replaced in pCCLsin.cPPT.ET.hFIX.wPRE.142-3pT 24 the wPRE sequence with the mutated mwPRE using the strategy described above. The full-length ORF of Sos1, Fign, Rtl1 and the truncated ORF of Braf, Sos1 and Fign starting from the exon downstream vector integrations were amplified by RT-PCR on RNA from murine liver with primers that added the restriction sites for MluI and SalI at the 5′ and 3′ of the ORFs, respectively. We then cloned the PCR products in MluI-SalI-digested pCCLsin.cPPT.ET.hFIX. mwPRE.142-3pT plasmid, thus replacing hFIX transgene with the ORF of the candidate cancer gene. In these LVVs carrying SIN LTRs, the expression of the transgene is regulated by the hepatospecific ET enhancer-promoter in internal position and by a 3′ UTR bearing target sequences for microRNA 142 (Mir142 target sequences). These SIN.ET.LV constructs allow high levels of transgene expression in hepatocytes by the activity of the ET promoter cloned in an internal position, and the SIN LTR design prevents the occurrence of insertional mutagenesis 3 . The Mir142 target sequences prevent any leaky expression of the transgene in hematopoietic cells in which Mir142 activity is high (i.e., Kupffer cells), thus avoiding a confounding transformation of nonhepatocyte cells and preventing immune response against the transgene that may cause clearance of the transduced cells 24 .
To generate vectors expressing neutral transgene as negative controls, we used pCCLSIN.cPPT.hPGK.EGFP.wPRE 41 to produce SINLV.PGK.EGFP.
We produced concentrated LVV stocks, pseudotyped with the VSV-G envelope, by transient cotransfection of four plasmids in 293T cells and titering on 293T cells as described 43 .
Mouse model generation and characterization. Cdkn2 −/− Ifnar1 −/− mice were generated to couple the high sensitivity to genotoxic mutations conferred by the Cdkn2a deficiency 3,41 to the high permissiveness to liver gene transfer by LVV conferred by the Ifnar1 deficiency 24 . Additionally, this noninflammatory tumor-prone mouse model has a clinical relevance because CDKN2A and its targets-pRB and p53-are frequently inactivated or silenced in human cancer 44 including HCCs 15 . Cdkn2 −/− (C57BL6/J) mice were obtained from NCI-Frederick MMHCC Repository, and Ifnar1 −/− (129SVEV) mice were obtained from B&K Universal. We generated F 1 Cdkn2a +/− Ifnar1 +/− mice by crossing Cdkn2 −/− mice with Ifnar1 −/− mice. By further crossing of F 1 Cdkn2a +/− Ifnar1 +/− mice, we generated F 2 mice with Mendelian ratios for each genotype; by allele-specific PCR screening, we identified F 2 Cdkn2 −/− Ifnar1 −/− mice ( Supplementary  Fig. 1b ) and further crossed them to get F 3 mice that were used for the insertional mutagenesis experiments. The phenotypes of Cdkn2 −/−13 and Ifnar1 −/−45 mice were previously described. Cdkn2 −/− Ifnar1 −/− mice were grown in the mouse facility, and their survival curve was characterized. Survival curves of Cdkn2 −/− Ifnar1 −/− and Cdkn2 −/− Ifnar1 +/− mice overlapped (median survival 255 and 229 d, respectively, Supplementary  Fig. 1c) . The survival curve of Cdkn2a −/− Ifnar1 +/+ mice was previously described (median survival ≈ 250 d) 8, 41 , and it overlapped with those of Cdkn2 −/− Ifnar1 −/− and Cdkn2 −/− Ifnar1 +/− mice. Therefore, Ifnar1 deficiency does not influence the development of Cdkn2a knockout-driven tumors. Histopathological analyses of untreated Cdkn2 −/− Ifnar1 −/− mice showed that they develop the same spectrum of hematopoietic malignancies and sarcomas described for Cdkn2 −/− mice 13 .
Mice with Pten tissue-specific knockout in hepatocytes were generated because they provide a model of inflammatory carcinogenesis associated with steatosis that mimics the non-alcoholic steatohepatitis disease 17 described in humans. Moreover, the model also has a clinical counterpart, as PTEN expression is reduced or absent in several human cancers, including almost 50% of advanced HCCs, and it is associated with a poor prognosis 18 . Pten flox/flox (129S4) mice that carry exon 5 of Pten surrounded by loxP sequences were obtained from Jackson Laboratories Mouse Repository. AlbCre + (C57BL6/J) mice that express Cre recombinase under the control of the hepatocytespecific albumin promoter were obtained from Weizmann Institute of Science. By crossing Pten flox/flox with AlbCre + mice, we generated F 1 AlbCre + Pten +/flox mice . By further crossing of AlbCre + Pten +/flox mice, we generated F 2 mice with Mendelian ratios for each genotype; by allele-specific PCR screening, we generated F 2 AlbCre + Pten flox/flox mice. The liver-specific deletion of Pten exon 5 was confirmed by PCR ( Supplementary Fig. 1d) . Through further crossing of AlbCre + Pten flox/flox mice, experimental AlbCre + Pten flox/flox mice (Pten liver-null throughout the text) were generated and used for the insertional mutagenesis experiments. AlbCre + Pten flox/flox mice were grown in our mice facility and euthanized at different ages to investigate the phenotype. AlbCre + Pten flox/flox mice generated in our laboratory matched the phenotype of a previous Pten liver-null model 17 , recapitulating the features of non-alcoholic steatohepatitis ( Supplementary  Fig. 1e) , which, after 40 weeks of age, progresses to hepatocellular adenoma and HCC (Supplementary Fig. 1f) .
The sequences of the primers used to perform PCR-based mouse genotyping are provided in Supplementary Table 5 .
The effects of carbon tetrachloride (CCl 4 ) administration on the mouse liver are well known 46, 47 . From the previous breeding, AlbCre − mice were also generated and included in the experimental outline as wild-type mice. Therefore, we set up an experimental model of chronic liver injury in wild-type mice by CCl 4 administration, which results in waves of hepatocyte necrosis and regeneration that cause liver damage without progression to cancer. In our rationale, in a chronic inflammatory microenvironment npg caused by CCl 4 treatment, cell clones harboring genotoxic LVV integrations will acquire additional synergizing genetic lesions that ultimately will be selected and lead to malignant transformation. Eight-week-old wild-type mice transduced or not with LV.ET.LTR at neonatal stage were administered CCl 4 at 1 mg/kg twice weekly for 6 weeks in a 10% mineral oil solution (Sigma). Histopathological analyses on the livers of mice analyzed at different time points after the end of the treatment showed that CCl 4 treatment induced mild steatosis and chronic inflammation (prototypical example in Fig. 1f) . The treatment with CCl 4 did not influence mouse survival by 1 year of age.
An additional panel of LVV-induced HCCs in the different mouse models is shown in Supplementary Figure 1g-n. Mouse treatments. For insertional mutagenesis experiments, newborn (24-to 48-h-old) mice from the three different genotypes (Cdkn2 −/− Ifnar1 −/− , AlbCre + Pten flox/flox and wild type) were administered 10 µl of highly concentrated LV.ET.LTR preparations by temporal vein injection (10 8 TU per mouse). To generate a data set of unselected integrations, we administered LV.ET.LTR to newborn mice of the three different genotypes (total n = 5) as described above and then euthanized at 2 weeks of age for liver sample collection.
To validate the oncogenicity of the newly identified cancer genes by liver gene transfer, newborn Cdkn2 −/− Ifnar1 −/− mice or wild-type mice were administered 20 µl of highly concentrated LVVs (2 × 10 7 -4 × 10 8 TU per mouse, according to vector titer; see Supplementary Table 3 ) that expressed the different cancer genes specifically in hepatocytes (see above). Wild-type mice were then administered the CCl 4 regimen as described above.
In our screening for cancer genes, we decided to transduce newborn mice to increase our chances of success in inducing HCC by LVV-based insertional mutagenesis. In a newborn mouse the hepatocytes are highly proliferating, thus promoting the accumulation of additional genetic and epigenetic lesions that may complement the 'time-zero' integrations in leading hepatocytes to transformation. Because carcinogenesis is a multistep process and the LVV integration provides just an early event, we transduced newborn mice with highly proliferating hepatocytes to favor the accumulation of mutations that usually takes years in the natural history of human hepatocarcinogenesis. Additionally, it was previously reported that the newborn mice are more sensitive than adult mice to hepatocyte transformation 42 .
All mice were bred and kept in a dedicated pathogen-free animal facility and were euthanized when they showed signs of severe sickness or at the defined time points: 20-30 weeks for Cdkn2 −/− Ifnar1 −/− mice, before significant mortality due to spontaneous hematopoietic malignancies is reached; 35 weeks for AlbCre + Pten flox/flox mice, to examine the effect of vector administration before the incidence peak of spontaneous liver tumors resulting from the genetic background; 52 weeks for wild-type mice because no spontaneous tumors are expected. All procedures were performed according to protocols approved by the Animal Care and Use Committee of the San Raffaele Institute (IACUC 353 and 463) and communicated to the Ministry of Health and local authorities according to Italian law.
Mouse sample collection and histopathology. By autoptical analysis we could identify grossly appearing masses in the liver parenchyma that were collected independently as well as nontumoral liver for microscopic and molecular analyses. One or two HCCs per liver were detected in Cdkn2 −/− Ifnar1 −/− mice at euthanasia, whereas up to five and up to seven liver tumors were collected from LVV-treated Pten liver-null and wild-type mice, respectively. Samples for DNA and RNA extraction were also collected from nontumoral liver parenchyma. A sample for DNA extraction was collected from every liver mass that was identified at autopsy; tumoral margins were estimated by gross appearance. A sample for RNA extraction was collected from only the tumoral masses whose size allowed the sampling (>3-mm diameter).
For histopathological analysis, liver lobes and all the collected liver masses were fixed in buffered 4% formalin and embedded in paraffin, and 3-µm sections were stained with hematoxylin and eosin. Each specimen was evaluated in blinded fashion and independently by two pathologists (F. Sanvito and C. Doglioni) with expertise in human and mouse histopathology. The liver tumors were classified according to World Health Organization Classification of Tumors 48 and were graded according to the modified Edmondson-Steiner grading system 49 . Photomicrographs were taken using the AxioCam HRc (Zeiss) with the AxioVision System 6.4 (Zeiss). Only samples collected from the liver masses that were identified as HCC by histopathology were used for the molecular analyses.
We evaluated the association between the integration within a specific CIS and HCC grade or the genetic background (Fig. 3a) by a two-tailed Fisher's exact test. HCCs with integrations targeting Sos1 were mainly of G1 (three out of four HCCs with Sos1 integration); but given the small number of HCCs with Sos1 integration, the co-occurrence of integration at Sos1 and Rtl1 in one HCC (that was grade 2), and the concomitant association between Fign integration and G1, no significant association to the tumor grade was found in this HCC collection (P = 0.2903, two-tailed Fisher's exact test).
AlbCre + Pten flox/flox mice also developed adenoma both from hepatocellular (mainly) and cholangiocellular (rare) origin. However, because of the high incidence of spontaneous adenomas in AlbCre + Pten flox/flox untreated mice (Supplementary Fig. 1f) , only the hepatocellular carcinomas found in the LVV-treated AlbCre + Pten flox/flox mice were used for the further analyses. We did not detect any cholangiocellular carcinomas in AlbCre + Pten flox/flox at 35 weeks of age.
Evaluation of liver transduction upon systemic LVV administration by immunofluorescence.
To test liver transduction by LVV systemic administration, we administered 5 × 10 7 TU per mouse of LV.PGK.EGFP 41 to 1-d-old Cdkn2 −/− Ifnar1 −/− mice (n = 5) that were then euthanized at 2-6 weeks. We fixed liver samples in 4% paraformaldehyde and equilibrated them in sucrose gradients for inclusion in OCT compound and freezing. We blocked 20-µm sections in PBS containing 1% bovine serum albumin and 5% FBS. We performed the staining with unconjugated rabbit anti-EGFP primary antibody (A11122, Invitrogen, dilution 1:200) and revealed by Alexa Fluor 488 donkey anti-rabbit secondary antibody (A21206, Invitrogen, dilution 1:500); cell nuclei were labeled by TO-PRO-3 (Invitrogen, 1:10,000). Confocal microscopy used an Axioskop 2 Plus direct microscope (Zeiss) equipped with a Radiance 2100 three-laser confocal device (Bio-Rad). Percentage of transduced hepatocytes npg was calculated as EGFP-positive polygonal cells with roundshaped euchromatic nuclei (i.e., hepatocytes) among total cells with round-shaped euchromatic nuclei. Three independent 20× fields were analyzed for each mouse (about 2,000 total hepatocytes per mouse). Administration of 5 × 10 7 TU per mouse of LV.PGK.EGFP resulted in an efficient transduction of the liver parenchyma, up to 60% of total hepatocytes.
Vector copy-number analysis. We extracted genomic DNA from nontumoral liver and liver masses using the Qiagen blood and cell culture and tissue DNA Kits (Qiagen). We performed qPCR analysis with primers and probes complementary to the mouse genomic Actb (β-actin) gene and a common LVV sequence in the ψ-signal region as described 41 . VCN was determined as the ratio between the relative amounts of LVV and total DNA (number of diploid genome) as evaluated by Actb. This calculation is possible because hepatocytes are still diploid in newborn mice at the time of transduction, and then the integrated provirus replicates together with the cellular genome. A standard curve was made using dilutions from murine DNA with a known LVV VCN determined by Southern blotting 50 . Reactions were carried out according to the manufacturer's instructions and analyzed using the ABI Prism 7900 HT Sequence Detection System (Applera, Life Technologies).
LAM-PCR and genomic integration site analysis.
LAM-PCR was performed as described 51 on all the histopathologically confirmed HCCs and representative nontumoral control samples. To favor the amplification of integrations occurring in the putatively oligoclonal tumor parenchyma over the ones occurring in the tumoral stroma and contaminating surrounding tissue, we used an ad hoc-designed LAM-PCR amplification protocol that uses limiting amounts of DNA to favor the amplification and retrieval of dominant insertions. For tumor samples, we used different amounts of DNA as template for LAM-PCR, according to the VCN that was detected in the sample by qPCR: 100 ng if VCN < 1; 50 ng if VCN ≥ 1 and ≤ 3; 10 ng if VCN > 3. For nontumoral samples, 100 ng of DNA was always used as template for LAM-PCR. LAM-PCR was initiated with a 25-cycle linear PCR and restriction digest using Tsp509I or HpyCHIV4. LAM-PCR primers for LVV were previously described [52] [53] [54] [55] . We separated LAM-PCR amplicons on Spreadex gels (Elchrom Scientific) to evaluate PCR efficiency and the bands pattern for each sample. Products of the second exponential amplification were tagged and then sequenced at high throughput with the 454 GS Flx platform (Roche).
Sequences were aligned to the mouse genome (assembly July 2007, mm9) using the NCBI BLAST genome browser (http://blast. ncbi.nlm.nih.gov/Blast.cgi) coupled to bioinformatic analyses.
Identification of the nearest gene was performed by bioinformatic analyses. A CIS was identified if at least four different integrations from independent tumors targeted a genomic region <100 kb, in accordance with the statistical definition of CIS developed in other studies 20, 21 . The closest gene to the CIS genomic region was considered as CIS gene.
Overall, LAM-PCR products from 30 LVV-induced HCCs were subjected to 454 pyrosequencing and generated 18,702 sequencing reads that, upon mapping on the murine genome, identified a total of 172 unique integration sites.
If we compare the data on the VCN from Supplementary Table 1 with the integration data presented in Supplementary Table 2 , it appears that there is not always a perfect match between the VCN and the number of integration mapped from each HCC mass. However, because tumoral margins were defined by gross appearance (and surrounding nontumoral liver parenchyma could have been collected as contaminant together with the HCC mass, especially when the HCC diameter measures <5 mm) and tumoral masses may contain several stromal cells, the VCN that we measured from the tumoral mass may be an inaccurate estimate of the actual VCN of tumoral cells. Additionally, LAM-PCR and mapping have intrinsic limitations that reduce their efficiency and can also identify integrations from transduced nontumoral cells that contaminate the tumoral mass. Therefore, we do not expect to find a perfect correlation between the VCN and the number of univocally mapped integrations for each single tumoral mass. Nonetheless, considering the whole collection of LVV-induced HCCs, we could find a significant correlation (P < 0.0001, R 2 = 0.5039, by Pearson correlation) between the VCN and the number of univocally mapped integrations retrieved from each HCC mass.
RNA isolation and transcriptome analyses of murine samples.
We isolated total RNA from tumor masses and nontumoral livers with the miRNeasy Mini Kit (Qiagen).
For the analysis of LV.ET.LTR-generated aberrant transcript, we performed RT-PCR reactions. We performed cDNA preparation using Mo-MLV reverse transcriptase and random hexamer primers (Invitrogen, SuperScript III First-Strand Synthesis System for RT-PCR). We performed PCR amplification using a sense primer on the vector transcript annealing on a sequence just downstream of the LTR transcription start site (LV.LTR_S) and antisense primers annealing on the exon downstream vector integrations in the targeted genes ( Supplementary Table 5 ). PCR products were purified (Qiagen), cloned into the TOPO TA vector (Invitrogen) and sequenced (Primm). We detected the generation of LVV-driven chimeric transcript from all the representative HCCs bearing integration at CISs that we analyzed by RT-PCR. We also detected the LVV-Braf fusion transcript from an additional HCC, even if integration studies failed to retrieve the LVV integration within Braf.
For whole-transcriptome studies, we performed microarray analysis (data deposited in GEO: GSE31409). We used total RNA (100 ng) for GeneChip analysis. We carried out the preparation of terminal-labeled cDNA, hybridization to the whole transcript GeneChip Mouse Gene 1.0 ST Array (Affymetrix) and scanning of the arrays according to the manufacturer's protocols (http:// www.affymetrix.com/). We performed a single microarray from each sample because it is the widely accepted standard when using Affymetrix commercial microarrays that contain internal quality controls. Each independent tumor that arose upon integration in a specific CIS represents a biological replicate. Therefore, considering the HCCs from which RNA was available for the gene expression analyses, we could analyze seven HCCs with integration in Fign, three HCCs with integration in Braf, two HCCs with integration in Sos1 and eight HCCs with integration in Rtl1.
Raw microarray data were preprocessed with the RMA algorithm. When fold-change expression is indicated, it refers to the mean ± s.d. for each group. We performed clustering analysis npg with unsupervised hierarchical methods with different distance (correlation and Euclidean) and linkage (average and centroid) by dCHIP software (http://www.biostat.harvard.edu/~cli/dchip_ 2010_01.exe) because we obtained overlapping results with different methods, a representative clusterization heat map is shown.
We validated the gene expression data obtained by microarray analysis by TaqMan RT-qPCR on representative samples and genes. We performed the cDNA preparation using Mo-MLV reverse transcriptase and random hexamer primers (Invitrogen, SuperScript III First-Strand Synthesis System for RT-PCR). We used cDNA as template for TaqMan Gene Expression Assays specific for each gene (Applied Biosystems). Primers and probes for the detection of Braf, Sos1 and Fign anneal at the 3′ portion of the gene, thus allowing the detection of both full-length and truncated transcripts. The TaqMan gene expression assays that we used are Mm01165837-m1 (for the detection of Braf), Mm02392620-s1 (for the detection of Rtl1), Mm00436730-m1 (for the detection of Sos1) and Mm03048240-m1 (for the detection of Sfrs4) (Applied Biosystems). We performed amplification reactions on a 7900HT real-time PCR thermal cycler. We calculated the relative expression level of each gene by the ∆∆ Ct method 56 , normalized to Sfrs4 expression (housekeeping control gene), and represented it as fold change relative to the mean of nontumoral liver samples (calibrator). We used Real-time PCR Miner software (http://www. miner.ewindup.info/) 57 to calculate the mean PCR amplification efficiency for each gene. We used the qBase software program (http://www.biogazelle.com/) to measure the relative expression level for each gene 58 . To detect both full-length and 5′-truncated transcripts generated by LV.ET.LTR integrations, we designed primers and probes at the 3′ end of Braf and Sos1 genes.
We performed analysis of the microarray data by gene set enrichment analysis (GSEA, http://www.broadinstitute.org/gsea/ index.jsp) 59 , comparing each murine HCC cohort to pooled nontumoral livers (from three Cdkn2a −/− Ifnar1 −/− , two Pten liver-null and three wild-type mice) or other HCCs with different integrations. GSEA overcomes several limitations of conventional GObased pathway analysis, which often fails to identify deregulated biological processes affecting sets of genes acting in concert. For example, critical pathways such as metabolic and transcriptional programs are biologically characterized by modest increases or reductions in the expression of an entire set of genes more often than large expression changes of individual genes belonging to the pathway. Such low-level gene deregulations are often highly relevant from a biological standpoint. Therefore, from an experimental perspective, GSEA presents two main methodological advantages. First, GSEA considers all of the genes in an experiment, not only those above an arbitrary cutoff in terms of fold change or significance. Second, GSEA assesses the significance by permuting the class labels, which preserves gene-gene correlations, providing a more accurate null model and attaching a meaningful statistical value to the results. Using GSEA, we could identify classes of genes specifically or commonly deregulated among different HCC groups. The Sos1 group could not be analyzed by GSEA because it was composed of only two samples (no permutation allowed). See also Supplementary Note 2.
For single-probe analysis at CIS genes, we obtained probelevel intensities from the GeneChip Mouse Gene 1.0 ST Array by performing the first two steps of RMA pipeline (RMA background correction and quantile normalization), thus excluding the summarization step. We calculated fold change in Figure 3c as the ratio between the mean expression level in a specific HCC group versus the mean expression level in pooled nontumoral livers for each single probe.
Western blotting. To test the efficiency of truncated protein expression of the SINLV used for the validation experiment, we transduced HepG2 cells (human hepatocytic cell line) with SINLV.ET.trSOS1 at a multiplicity of infection of 10 and analyzed them 2 weeks after transduction. Western blotting was performed on HepG2 cells transduced with LV.ET.LTR (negative control) or SINLV.ET.trSOS1. We also analyzed representative HCCs induced in the cancer gene screening with LV.ET.LTR and HCCs induced by SINLVs in the validation experiment (see Supplementary  Fig. 2c,d and Supplementary Tables 1 and 3 for mouse and tumor IDs). We extracted total cellular proteins from cells and HCCs with RIPA buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100) supplemented with protease inhibitor cocktail (Sigma). We homogenized the samples in the lysis solution and incubated them at 4 °C for 30 min. Cell lysates were cleared by centrifugation at 10,000g for 10 min at 4 °C, and the supernatants were collected and assayed for protein concentration using Quick Start Bradford dye reagent (BioRad). 30-60 µg of proteins were run with SDS-PAGE under reducing conditions. For immunoblotting, we transferred proteins to nylon membranes by iBlot dry blotting system (Invitrogen); the membranes were then blocked in 5% nonfat dry milk in a solution of TBS 1× Tween 0.1% and incubated with the specific primary antibody followed by peroxidase-conjugated secondary antibodies (anti-mouse or anti-rabbit IgG horseradish peroxidase (HRP)-conjugated for secondary detection: #715-035-150 and #711-035-152, Jackson ImmunoResearch; dilution: 1/10,000). The signal was detected with HRP chemiluminescent substrate (SuperSignal West Dura chemiluminescent substrate, Thermo Scientific, or ECL prime, Amersham) and exposure to autoradiography films (Amersham Hyperfilm, GE Healthcare). We used the following primary antibodies: rabbit polyclonal anti-SOS1 (LS-C10294, LifeSpan BioSciences; 1:1,000), which is raised against an epitope at the C terminus of the protein (corresponding to amino acids 1,243-1,258) and binds both human and murine SOS1; mouse anti-tubulin (T9026, Sigma; dilution 1/50,000) that binds both human and murine β-tubulin; and mouse anti-GAPDH (G9545, Sigma, 1:10,000) that binds efficiently human GAPDH and less efficiently to murine GAPDH.
Gene expression on human samples. We used archival human samples following the rules of the Ethical Committee of Hospital of Saint Rafael (HSR). Each human specimen was evaluated in blinded fashion and independently by two pathologists (F. Sanvito and C. Doglioni) with expertise in human and mouse histopathology. The liver tumors were classified according to World Health Organization Classification of Tumors 48 and were graded according to the modified Edmondson-Steiner grading system 49 . The HCC collection harvested in our institution (HSR collection) is formed by 14 liver tumors (1 adenoma; 1, 9 and 3 HCCs of G1, G2 and G3, respectively) and 14 patient-matched nontumoral liver samples.
We isolated total RNA from human HCC and patient-matched nontumoral liver with the miRNeasy Mini Kit (Qiagen). We performed npg cDNA preparation using Mo-MLV reverse transcriptase and random hexamer primers (Invitrogen, Superscript III First-Strand Synthesis System for RT-PCR). We used cDNA as the template for TaqMan Gene Expression Assays specific for each gene (Applied Biosystems). Primers and probes for the detection of BRAF, SOS1 and FIGN detect the 3′ portion of the gene. The TaqMan gene expression assays that we used are Hs00269944-m1 (for the detection of BRAF), Hs00250679-s1 (for the detection of FIGN) , Hs00893134_m1 (for the detection of SOS1) and Hs00194538-m1 (for the detection of SFRS4) (Applied Biosystems).
We performed amplification reactions on a 7900HT real-time PCR thermal cycler. We calculated the relative expression level of each gene by the ∆∆ Ct method 56 , normalized to SFRS4 expression (housekeeping control gene), and represented it as fold change relative to the nontumoral liver (calibrator). We used Real-time PCR Miner software 57 to calculate the mean PCR amplification efficiency for each gene. We used the qBase software program to measure the relative expression level for each gene 58 .
Data mining of gene expression and CGH data.
We analyzed a data set of 75 human samples (Mount Sinai School of Medicine (MSSM) collection; GEO: GSE6764 (ref. 25) including normal liver (n = 10) and liver with cirrhosis (n = 13), low-grade dysplasia (n = 10), high-grade dysplasia (n = 7), very early HCC (n = 8), early HCC (n = 10), advanced HCC (n = 7) and very advanced HCC (n = 10), for a total of 40 nontumoral samples and 35 HCCs. These samples were referred to in the manuscript as MSSM sample collection. These patients were mainly affected by hepatitis C virus infection 25 .
By the SAM (significance analysis of microarray) approach, we analyzed our murine microarray data described above and identified gene expression signatures specifically associated to the different cancer genes (Braf, Fign and Rtl1) with a false discovery rate of <0.01. By GSEA, we compared and contrasted the probe sets deregulated in the different disease groups in the human samples with the murine HCC subgroups. By this approach, we evaluated how the genes specifically deregulated in murine CIS-specific groups of HCC are deregulated in different classes of human samples in this data set 25 . As for the single-gene analysis, we calculated the fold change in Figure 5a -c versus the mean of normal liver samples. See also Supplementary Note 3.
We performed clustering analysis with unsupervised hierarchical methods with different distance (correlation and Euclidean) and linkage (average and centroid) by dCHIP software; because similar results were obtained with different methods, a representative clusterization is shown (correlation distance and centroid linkage).
We retrieved additional gene expression or CGH data on murine and human samples by data mining using the OncoDB. HCC database (http://oncodb.hcc.ibms.sinica.edu.tw/, see also Supplementary Note 4), Oncomine web resource (http:// www.oncomine.org/) and GEO web resource (http://www.ncbi. nlm.nih.gov/geo/).
Correlation between gene expression and clinical outcome of patients affected by HCCs.
We could access the clinical data of 70 patients affected by hepatitis B virus-induced HCCs 27 ; the gene expression data were publicly available by GEO GSE15765.
Because the Affymetrix Human Genome U133A 2.0 Array was used, only 14,500 well-characterized human genes were detected; unfortunately, some genes of interest were lacking on the array, such as FIGN and RTL1. We divided patients into two groups according to the expression level of SOS1, BRAF (above or below the mean expression level of each gene in the entire collection of HCCs), and we compared the survival curve and disease-free survival curve between the two groups with GraphPad Prism, applying both the log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test. For instance, for SOS1, we divided patients into two groups: those carrying HCCs that displayed SOS1 expression levels above SOS1 mean expression in the HCC collection and those carrying HCCs that displayed SOS1 expression levels below mean SOS1 expression; n = 40 and n = 30, respectively. Analysis of survival curves showed that patients bearing HCC with high expression of SOS1 have a significantly increased overall survival as compared to patients bearing HCC with low SOS1 levels (by both the Gehan-Breslow-Wilcoxon test and log-rank Mantel-Cox test).
We used the cancer gene-specific gene expression signatures identified in the LVV-induced HCCs in mice by SAM (FDR < 0.01) to perform hierarchical clustering of the 70 HCCs from the microarray data set. We performed clustering analysis with unsupervised hierarchical methods with different distance (correlation and Euclidean) and linkage (average and centroid) by dCHIP software; because similar results were obtained with different methods, a representative clusterization was considered and shown (correlation distance and centroid linkage). By this approach, we generated a hierarchical clustering tree and identified two main sample clusters. Then we compared the survival curves and disease-free survival curves between the two clusters using GraphPad Prism, applying both the log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test. We also analyzed the main clusters of genes that were differentially expressed among the sample clusters by Ingenuity IPA pathway analysis software (Ingenuity Systems, http://www.ingenuity.com/) to identify the main biological functions associated to these genes.
